Last update 01 Jul 2024
Estriol
Last update 01 Jul 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms (16α,17β)-estra-1,3,5(10)-triene-3,16,17-triol, 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol, 16-alpha-Hydroxyestradiol + [18] |
Target |
Mechanism ERs agonists(Estrogen receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (18 Nov 1960), |
Regulation- |
Login to view First Approval Timeline
Structure
Molecular FormulaC18H24O3 |
InChIKeyPROQIPRRNZUXQM-ZXXIGWHRSA-N |
CAS Registry50-27-1 |
Related
36
Clinical Trials associated with EstriolEffect of Local Estriol Treatment Before Vaginal Repair Surgery on Vaginal Tissues and Early Postoperative Pelvic Floor Functions
GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.
Correction of Vulvovaginal Atrophy in Postmenopausal Women Using Neodymium Laser Treatment
100 Clinical Results associated with Estriol
Login to view more data
100 Translational Medicine associated with Estriol
Login to view more data
100 Patents (Medical) associated with Estriol
Login to view more data
4,737
Literatures (Medical) associated with Estriol01 Apr 2024Food chemistry
Membrane–protected magnetic covalent organic framework for efficient extraction of estrogens in dairy products
Article
Author: Xu, Jin-Jie ; Yang, Cheng ; Shen, Xiao-Fang ; Pang, Yue-Hong ; Mo, Zheng-Lian ; Zhang, Qiu-Fang
The presence of estrogens residues in dairy products is a growing concern due to their potential health risk. Herein, in this study, we have developed a membrane-protected magnetic solid-phase extraction (MP-MSPE) method that utilized a magnetic adsorbent (Fe3O4@COF-LZU1) with in-situ growth for the efficient extraction of estrone (E1), 17β-estradiol (E2), and estriol (E3). When combined with HPLC-FLD, this method allows for the efficient detection of estrogens in dairy products. The stability of the MP-MSPE was improved by the presence of a dialysis membrane, which remained a high extraction efficiency (90 %) even after ten reuse cycles. The hydrogen bonding, π-π interactions and pore size effect contribute to the excellent adsorption of three estrogens onto Fe3O4@COF-LZU1. Under optimal conditions, the method exhibits a low detection limit (0.01-0.15 μg L-1), wide linear range (0.1-800 μg L-1), and favorable recoveries (77.3 %-109.4 %) at three concentration levels (10, 50 and 100 μg L-1). This proposed method is characterized by its simplicity, high efficiency and eco-friendliness, making it a promising approach for extracting estrogens from dairy products.
01 Mar 2024Multiple sclerosis and related disorders
Estriol and commensal microflora strains regulate innate lymphoid cells functional activity in multiple sclerosis
Article
Author: Danchenko, Irina ; Shirshev, Sergei ; Glebezdina, Natalia ; Maslennikova, Irina ; Nekrasova, Irina
Multiple sclerosis (MS) is an autoimmune neurodegenerative disease in which the immune system attacks myelin basic protein of nerve axons. Recently, there has been growing interest in studying the role of a newly described population of immunity cells - innate lymphoid cells (ILCs) in the pathogenesis of the disease. At the same time, it was found that during pregnancy there is a weakening of Th1-mediated autoimmune pathologies manifestations, including MS. In this work, we studied phenotypic characteristics of ILC in MS patients in comparison with healthy donors after 48 h incubation with pregnancy hormone estriol (E3) and commensal microflora cells. To activate ILC, strains of Ecsherichia coli K12 and Lactobacillus plantarum 8R-A3 were used. ILC phenotype was assessed by flow cytometry using monoclonal antibody staining. It has been established that E3 and bacterial factors are able to regulate the maturation of ILC subtypes and their cytokines in different ways. In general, the studied factors influence the phenotypic changes in ILC cells, leading to the transition from one type to another, both in healthy donors and in MS patients.
01 Mar 2024Ophthalmology science
Prospective Observational Study Evaluating Systemic Hormones and Corneal Crosslinking Effects in Keratoconus
Article
Author: Van, Lyly ; Nicholas, Sarah E ; Hjortdal, Jesper ; Bennett, Sashia ; McKay, Tina B ; Karamichos, Dimitrios
Purpose:
To evaluate associations between hormone levels and corneal parameters in patients with keratoconus (KC), before and after photooxidative corneal collagen crosslinking (CXL).
Design:
Prospective, observational cohort study.
Participants:
Twenty-eight patients with KC who were scheduled for CXL at Aarhus University Hospital in Denmark.
Methods:
Androgen (dehydroepiandrosterone sulfate [DHEA-S]) and estrogen (estrone and estriol) plasma levels were measured and clinical assessments were performed before CXL and 2 to 3 months post-CXL, comparing the CXL eye with the control eye from the same participant.
Main Outcome Measures:
Associations between hormone levels and maximum corneal curvature (Kmax) and minimum central corneal thickness (CCtmin) before and after CXL.
Results:
Corneal collagen crosslinking was associated with a 2% reduction in Kmax values in the CXL eye, post-CXL, from baseline (median, 56.8 diopters [D]; 95% confidence interval [CI], 50.4-60.3) to the second visit (55.7 D; 95% CI, 50.4-58.8; P < 0.001). Systemic DHEA-S levels were 5 to 6 orders of magnitude higher than estriol or estrone concentrations in plasma. Importantly, estriol levels, rather than DHEA-S or estrone levels, were more closely correlated with Kmax before CXL (Spearman's r = 0.55, P = 0.01). Post-CXL Kmax and CCtmin were not associated with DHEA-S, estrone, or estriol plasma levels at the same timepoint.
Conclusions:
This study provides supporting evidence based on a KC clinical population that systemic estrogen levels may influence corneal parameters (curvature and thickness) pre-CXL. Further studies evaluating the interplay between the therapeutic benefits of CXL and systemic hormone distributions are needed to determine if perturbation of the local corneal microenvironment influences endocrine function.
Financial Disclosures:
The authors have no proprietary or commercial interest in any materials discussed in this article.
2
News (Medical) associated with Estriol
100 Deals associated with Estriol
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Infertility | CN | - | 01 Jan 2000 |
| Vulvovaginal atrophy | GB | 20 Aug 1982 | |
| Osteoporosis | JP | 28 Dec 1981 | |
| Menopausal symptoms | JP | 18 Nov 1960 | |
| Uterine Cervical Erosion | JP | 18 Nov 1960 | |
| Uterine Cervicitis | JP | 18 Nov 1960 | |
| Vaginitis | JP | 18 Nov 1960 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| vaginal mucosa dry | Phase 2 | CZ | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | HU | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | IT | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | ES | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | SE | 01 Oct 2016 | |
| Atrophic Vaginitis | Phase 2 | ES | 16 Oct 2015 | |
| Atrophic Vaginitis | Phase 2 | SE | 16 Oct 2015 | |
| Early Stage Breast Carcinoma | Phase 2 | ES | 16 Oct 2015 | |
| Early Stage Breast Carcinoma | Phase 2 | SE | 16 Oct 2015 | |
| Multiple Sclerosis | Phase 2 | US | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 167 | (0.005% Estriol Group) | unqegfkvaq(cffyalsozq) = ihgudfgwaa rzkpzzypnm (mzjtrvznzr, tjacsbbcfe - dnbvrqcthq) View more | - | 11 Dec 2020 | ||
Placebo (Placebo Group) | unqegfkvaq(cffyalsozq) = jzukfwgstj rzkpzzypnm (mzjtrvznzr, fvypycaxns - qsqeurrksh) View more | ||||||
Phase 2 | 283 | (Estriol 0.005%) | ksotwkquna(jpuijzllrf) = wrznjoiogc aqdsxxqrxu (tcbiyosnwi, xvxhqjumqn - rcyxfmmvtk) View more | - | 25 Sep 2019 | ||
(Estriol 0.002%) | ksotwkquna(jpuijzllrf) = cyrzbdcybd aqdsxxqrxu (tcbiyosnwi, dnstryjuzt - apyheabtmj) View more | ||||||
Phase 2 | 61 | (0.005% Estriol Vaginal Gel) | gsbjizjdrs(lmshotkrso) = yhtmfuhwwv gtmirbpqyc (rypjajgcmr, copwexkwwn - erzhzfvbvu) View more | - | 05 Aug 2019 | ||
Placebo (Placebo Vaginal Gel) | gsbjizjdrs(lmshotkrso) = ncvizimdxa gtmirbpqyc (rypjajgcmr, cwwwprhmqt - xtslgzeedd) View more | ||||||
Phase 2 | 123 | (Bevacizumab Spray) | ywlrzrbhzj(bfoguibocd) = jjsqytbmxx yiumwrxgqd (jeoewwhwob, twjbcfhrgf - jpavzkyphm) View more | - | 19 Oct 2018 | ||
(Estriol Spray) | ywlrzrbhzj(bfoguibocd) = tpyjsuiswg yiumwrxgqd (jeoewwhwob, bkcxouiykf - ilmvipvwin) View more | ||||||
Phase 2 | - | 21 | (Study Arm 1) | nwluypfcte(qylfblomeo) = mkbtghtmus dzbonwxpzc (zcjltgrpyl, wsmtcmlfit - xbbyojefuv) View more | - | 16 May 2018 | |
(Study Arm 2) | nwluypfcte(qylfblomeo) = ouomboripi dzbonwxpzc (zcjltgrpyl, gxaegmohqk - taqaohlsha) View more | ||||||
Phase 2 | 158 | uzmpqlufmo(regwfgrvgr) = pwtshllkcj zpvfxrlpgj (oihtsrnvzp, yeipxzuibb - bbtwdlsxkv) View more | - | 16 Jun 2016 | |||
Placebo+Copaxone (Placebo Capsules Plus Copaxone Injections) | uzmpqlufmo(regwfgrvgr) = zzfwcnxocf zpvfxrlpgj (oihtsrnvzp, fxzkimtezf - psfzqohrci) View more | ||||||
Phase 2 | 164 | xgflkzfcge(aweionpkme) = gywsbibjyx ihxqmmokzw (mbxmludkep, 0.17 ~ 0.37) View more | Positive | 01 Jan 2016 | |||
Placebo | xgflkzfcge(aweionpkme) = eeqnbcwhkv ihxqmmokzw (mbxmludkep, 0.25 ~ 0.53) View more | ||||||
Phase 2 | - | Estriol 8 mg per day + Glatiramer Acetate | tjzuebdfxh(xichpvaatz) = Trends for improvement at 24 months in the estriol plus glatiramer acetate group, but not in the placebo plus glatiramer acetate group kvxqcmbrsv (itokeoquof ) | Positive | 09 Sep 2014 | ||
Placebo + Glatiramer Acetate | |||||||
Phase 3 | 63 | (Estriol) | idwxgbxwxu(ranhpeudxf) = kbbpuwigtt kltruwkdyw (nhwcitbrjv, xouviqmjub - yjywrkuruq) View more | - | 28 Mar 2014 | ||
(Estradiol) | idwxgbxwxu(ranhpeudxf) = bwxfktmtcv kltruwkdyw (nhwcitbrjv, aywfuigihy - glqsyblfkp) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free